Heartburn Remedies

πŸ”₯+ Heartburn Remedies 10 Jul 2020 Think you have acid reflux? You may not. Plusβ€”the latest on treating chronic heartburn. Written by Robin Tricoles.

Heartburn Remedies Well, they do! Artificial sweeteners have a lot to do with making acid reflux much worse and may even be among the initial causes of reflux.

Acid Reflux Every Meal
Gut Liver. 2017 Jan; 11(1): 27–37.
Published online 2016 Nov 14. Heartburn Remedies Foods That Fight Hearbturn (⭐️ Symptoms) | Heartburn Remedies Common Heartburn Triggershow to Heartburn Remedies for doi: 10.5009/gnl15502
for 1 last update 10 Jul 2020 PMCID: PMCID: PMC5221858
PMID: 27840364

Daniel S. Strand

1Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA

Find articles by Daniel S. Strand

Daejin Kim

2Division of Gastroenterology, Daegu Fatima Hospital, Daegu, Korea

Find articles by Daejin Kim

David A. Peura

Heartburn Remedies Home Remedies (πŸ”΄ Naturally Treat) | Heartburn Remedies Instant Heartburn Reliefhow to Heartburn Remedies for 1Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA

Find articles by David A. Peura
1Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA
2Division of Gastroenterology, Daegu Fatima Hospital, Daegu, Korea
Correspondence to: Daniel S. Strand, Division of Gastroenterology and Hepatology, University of Virginia, PO Box 800708, Charlottesville, VA 22908, USA, Tel: +1-434-297-7207, Fax: +1-434-244-7590, E-mail: [email protected]
Received 2015 Oct 5; Accepted 2016 Feb 7.
Copyright © 2017 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article has been cited by other articles in PMC.

Abstract

Heartburn Remedies GERD (πŸ”΄ Heartburn) | Heartburn Remedies What Causes Heartburnhow to Heartburn Remedies for Proton pump inhibitors (PPIs) were clinically introduced more than 25 years ago and have since proven to be invaluable, safe, and effective agents for the management of a variety of acid-related disorders. Although all members in this class act in a similar fashion, inhibiting active parietal cell acid secretion, there are slight differences among PPIs relating to their pharmacokinetic properties, metabolism, and Food and Drug Administration (FDA)-approved clinical indications. Nevertheless, each is effective in managing gastroesophageal reflux disease and uncomplicated or complicated peptic ulcer disease. Despite their overall efficacy, PPIs do have some limitations related to their short plasma half-lives and requirement for meal-associated dosing, which can lead to breakthrough symptoms in some individuals, especially at night. Longer-acting PPIs and technology to prolong conventional PPI activity have been developed to specifically address these limitations and may improve clinical outcomes.

Keywords: Proton pump inhibitors, Review, Pharmacokinetics, Indications, Risk

INTRODUCTION

Since the introduction of omeprazole in 1989, proton pump inhibitors (PPIs) have steadily become the mainstay in treatment of acid-related disorders. When compared with earlier agents such as histamine2-receptor antagonists (H2RAs), synthetic prostaglandin analogs, and anticholinergics, PPIs have demonstrated consistent patient tolerance, excellent safety, and generally superior acid suppressing capability than prior agents.1,2

As of 2015, there are six PPIs approved by the the 1 last update 10 Jul 2020 United States Food and Drug Administration (FDA) (Table 1).3 Adoption of PPI use has been widespread among primary care providers, and their presence is ubiquitous within the armamentarium of the modern gastroenterologist. For most, this class of drugs represents the first choice for treatment of esophagitis, nonerosive reflux disease (NERD), peptic ulcer disease (PUD), prevention of nonsteroidal anti-inflammatory drugs (NSAID) associated ulcers, Zollinger-Ellison syndrome (ZES), and functional dyspepsia.46 In combination with antibiotics, PPIs are also an integral part of eradication therapy for Helicobacter pylori.7As of 2015, there are six PPIs approved by the United States Food and Drug Administration (FDA) (Table 1).3 Adoption of PPI use has been widespread among primary care providers, and their presence is ubiquitous within the armamentarium of the modern gastroenterologist. For most, this class of drugs represents the first choice for treatment of esophagitis, nonerosive reflux disease (NERD), peptic ulcer disease (PUD), prevention of nonsteroidal anti-inflammatory drugs (NSAID) associated ulcers, Zollinger-Ellison syndrome (ZES), and functional dyspepsia.46 In combination with antibiotics, PPIs are also an integral part of eradication therapy for Helicobacter pylori.7

Table 1

Commercially Available Proton Pump Inhibitors in the United the 1 last update 10 Jul 2020 StatesCommercially Available Proton Pump Inhibitors in the United States

DrugDosages, mgIVLiquid or suspensionGenericOver-the-counter
Omeprazole10, 20, 40YesNoYesYes
Esomeprazole20, 40YesYesYesYes
Lansoprazole15, 30YesYesYesYes
Dexlansoprazole30, 60NoNoNoNo
Pantoprazole20, 40YesYesYesNo
Rabeprazole20NoNoYesNo

Despite an excellent safety profile throughout their first two decades of use, the nearly universal popularity of PPIs has prompted several concerns about both their short- and long-term effects.8,9 This review will examine the pharmacokinetics and pharmacodynamics of these drugs and provide an update on both the clinical use of and remaining for 1 last update 10 Jul 2020 challenges with PPIs.Despite an excellent safety profile throughout their first two decades of use, the nearly universal popularity of PPIs has prompted several concerns about both their short- and long-term effects.8,9 This review will examine the pharmacokinetics and pharmacodynamics of these drugs and provide an update on both the clinical use of and remaining challenges with PPIs.

WHAT ARE PPIs AND HOW DO THEY WORK?

All currently approved PPIs are benzimidazole derivatives: heterocyclic organic molecules that include both a pyridine and benzimidazole moiety linked by a methylsulfinyl group. The prototypical example of this structure, omeprazole, was the first clinically useful PPI. Subsequently introduced drugs include lansoprazole, pantoprazole, rabeprazole and the stereo-isomeric compounds esomeprazole and dexlansoprazole.10 Although each of these drugs has different substitutions on their pyridine and/or benzimidazole rings, in general they are remarkably similar in their pharmacological properties.

More recently, the novel imidazopyridine PPI, tenatoprazole has undergone preliminary preclinical and clinical evaluation. Though not yet approved for clinical use, this new subset of PPI with a prolonged half-life may ultimately offer advantages over its benzimidazole cousins.10

Heartburn Remedies List Of (⭐️ Acidity) | Heartburn Remedies Heartburnhow to Heartburn Remedies for PPIs are membrane permeable, acid-labile weak bases. In order to prevent premature activation and degradation by luminal gastric acid, these drugs are packaged in a variety of delivery systems. These include enteric-coated tablets, gelatin capsules, or coated granules supplied as a powder for suspension. They also may be packaged in combination with bicarbonate to confer temporary luminal pH neutralization. Once clear of the stomach, PPIs are absorbed in the proximal small bowel. There are also intravenous (IV) formulations available for lansoprazole, pantoprazole, and esomeprazole, which provide immediate acid suppression and are well suited for hospitalized patients in whom the oral route of administration is not appropriate.10 The serum half-life of single release PPIs is extremely short (1 to 2 hours), though considerable effort has been made to develop dual release/or delayed release formulations to counteract this short-coming.11,12 Imidazopyridines such as tenatoprazole, which have a serum half-life of 7 hours, may also overcome this weakness and potentially demonstrate added clinical benefit in the future.10

Once absorbed, circulation transits the PPIs to activated gastric parietal cells where they concentrate within the acidic secretory canaliculi. Here, the PPI undergoes acid-catalyzed cleavage of a chiral sulfoxide bond (except esomeprazole and dexlansoprazole which are nonchiral) into active sulfenic acid and/or sulfonamide. These compounds then bind covalently to cysteine residues on the H+/K+ ATPase and act to inhibit acid secretion until replacement pumps can be synthesized (up to 36 hours).10 Although frequently considered equivalently effective with respect to clinical parameters, the specific pharmacologic properties among individual PPIs are somewhat different (Table 2).13

Table 2

Heartburn Remedies The Discomfort (πŸ”΄ Foods That Fight Hearbturn) | Heartburn Remedies 10 Home Remedieshow to Heartburn Remedies for Pharmacokinetic Properties of Proton Pump Inhibitors

OmeprazoleEsomeprazoleLansoprazoleDexlansoprazolePantoprazoleRabeprazole
Bioavailability, %30–4064–9080–85-7752
Time to peak plasma level (tmax, hr)0.5–3.51.51.71–2, 4–52–32–5
Protein binding, %959797969896.3
Half-life, hr0.5–11–1.51.61–21–1.91–2
Primary excretionHepaticHepaticHepaticHepaticHepaticHepatic
Liver metabolismCYP2C19CYP2C19CYP2C19CYP2C19
CYP3A4
CYP2C19
CYP3A4
CYP2C19

PPIs require the active canaliculi expression of H+/K+ ATPases for binding which occurs in response to a meal. During a single meal, neither all parietal cells nor all of its proton pumps are active. Only about two-thirds of proton pumps are inhibited by a single PPI dose, which leaves up to one-third of pumps uninhibited. With future meals, as previously inactive enzymes are recruited into the secretory canaliculi, proton exchange will again increase (though attenuated). This physiology is the rationale both for preprandial dosing (important due to short serum half-life) and the observation of escalating pharmacologic efficacy of PPIs after multiday treatment.10

PPIs are highly protein bound and subject to degradation by hepatic P450 cytochromes. Although the CYP2C19 pathway is dominant overall, individual agents have variations which have led to concerns over efficacy and drug-drug interaction.14 Omeprazole and its stereo-isomer esomeprazole are metabolized almost entirely by CYP2C19, thereby offering the greatest potential for interaction with other drugs. Rabeprazole and lansoprazole/dexlansoprazole are also metabolized by CYP2C19, but they possess significant affinity for CYP3A4. Interactions appear less significant with these agents, perhaps owing to this difference. Pantoprazole, on the other hand, is primarily degraded by CYP2C19 O-demethylation and sulfate conjugation which results in the lowest potential for cytochrome induction or inhibition among the benzimidoles.15 It is our practice to favor pantoprazole or lansoprazole/dexlansoprazole in patients where this interplay of drug metabolism is a primary concern (i.e., patients with high risk for cardiovascular events who are on clopidogrel). Following hepatic metabolism, the ultimate excretion of most benzimidoles is renal, though lansoprazole/dexlansoprazole are also excreted via the biliary tree.6 While controversial, there are data to suggest that patients who are genetically rapid drug metabolizers, a situation more commonly encountered in Europe and North American, may be less likely to fully respond to their PPI treatment, especially H. pylori eradication than slower metabolizers of the drugs.15

CLINICAL ADVANTAGES OF PPIs

Gastric acid secretion is a multifactorial and complex process regulated by at least three different stimuli upon the parietal cell. These pathways include the paracrine elaboration of gastrin and histamine, as well as the actions of postganglionic muscarinic acetylcholine. Unlike anticholinergics and histamine2-receptor blockers, PPIs inhibit the final common pathway of acid secretion (the H/K ATPase) in response to any and all stimulation of the parietal cell.1,16

The PPIs represent the most potent inhibitors of gastric acid secretion available since, as noted above, they directly block the acid pump itself. Their superior biochemical effect compared with H2RAs is based upon their ability to reliably maintain intragastric pH >4 for between 15 and 21 hours daily, as compared to only 8 hours for H2RAs.16 In addition to being more long lasting, the effectiveness of PPIs is also superior with respect to postprandial and nocturnal intragastric pH control, which is of clinical importance in some patients.17 This effect of PPIs is also maintained over the long-term without the need for dose escalation. In contrast, tachyphylaxis may occur with H2RAs as rapidly as within 3 to 5 days of regular use.18 While the short-term implications of this difference may not be relevant, consistent use of H2RAs over a period of weeks to months may reduce their acid-suppressing effect nearly in half.19

GENERAL CLINICAL USES OF PPIs

Heartburn Remedies Best Practices (⭐️ Acid Reflux) | Heartburn Remedies Help Relievehow to Heartburn Remedies for 1. Healing of PUD

While the underlying pathophysiology of gastric and duodenal ulcer disease is disparate, acid suppression remains the mainstay of treatment for both conditions. In both cases, the sustained neutralization (pH>3) of gastric acid over 18 to 20 hours per day is an important determinant in healing.2,20

Clinical trials have consistently shown superior healing rates for gastroduodenal ulcers with PPI therapy than with H2RAs. A meta-analysis which included 30 double-blind prospective trials of omeprazole (20 mg daily) compared with either ranitidine or cimetidine demonstrated an overall therapeutic gain of 15.2% in healing for duodenal ulcer (p<0.001) and 9.9% for gastric ulcer (p<0.005) after only 2 weeks of treatment. In addition, a greater percentage of patients were also free of symptoms at first follow-up when treated with PPIs.21 Pooled data from 384 randomized controlled trials (RCTs) which included a total of 44,870 patients concluded that omeprazole was significantly more effective (p=0.001) than H2RAs in achieving ulcer healing, with overall rates of 80.8% and 74.7%, respectively.22 Similar results with lansoprazole,23 rabeprazole,24 and pantoprazole25 confirm a class advantage in favor of PPIs.

Heartburn Remedies Causes (πŸ”₯ Quick Relief) | Heartburn Remedies 10 Remedieshow to Heartburn Remedies for After initial healing, maintenance therapy is an important consideration in high-risk patient groups such as those with PUD related complications, recurrences, or H. pylori negative ulcers. In a RCT including 195 patients, 20 mg of omeprazole given 3 days per week (q AM Friday through Sunday) reduced the incidence of recurrent duodenal ulcer when compared to placebo from 67% to 23% (p<0.001).26 There are similar data for maintenance and prevention with lansoprazole (15 mg).27 Although clinical trials describe dosing of PPIs for maintenance for up to 12 months, the ideal duration of therapy is not known and prolonged treatment may be unnecessary if H. pylori is eradicated. It should also be noted that the continuous use of H2RAs are similarly effective at preventing ulcer recurrence compared to placebo (20% to 25% vs 60% to 90%).28 We favor the use prolonged use of PPIs when coincident clinical concerns exist (e.g., persistent symptoms), when H2RAs have proven ineffective, in the setting of NSAID associated or non-H. pylori related ulcer, or when there have been ulcer-related complications (e.g., perforation and fibrosis) at the outset.

2. Peptic ulcer related gastrointestinal bleeding

Upper gastrointestinal (UGI) bleeding due to PUD is an important emergency medical condition which results in very high patient morbidity, health care costs, and mortality.29,30 While rapid assessment, best supportive care, and prompt endoscopic diagnosis and hemostasis are the mainstays of modern societal recommendations,3032 the method and dose of antisecretory PPI therapy remains an important consideration. A Cochrane systematic review of six high-quality RCTs (n=2,223) demonstrated that there was no improvement in overall mortality (6.1% vs 5.5%; odds ratio [OR]=1.12, 0.72–1.73), rebleeding (13.9% vs 16.6%; OR=0.81, 0.61–1.09), or surgery (9.9% vs 10.2%; OR=0.96, 0.68–1.35) in patients who received pre-endoscopic PPI therapy.33 Despite this lack of improvement in hard outcomes, preadministration of PPI was noted to reduce the proportion of patients who had high-risk stigmata of hemorrhage by Forrest classification at the time of initial endoscopic exam (37.2% vs 46.5%; OR=0.67, 0.54–0.84). Furthermore, an analysis of patients in trials where endoscopic hemostatic therapy was inconsistently used, early PPI therapy was associated with reduced rebleeding (OR=0.38, 0.18–0.81) and the need for surgery (OR=0.62, 0.44–0.88). Given these data, along with the favorable risk profile of early PPI use, it is our practice to initiate a high dose IV bolus (pantoprazole or esomeprazole) and continuous infusion until endoscopic diagnosis can be ascertained. After endoscopy, the continuation of treatment and dose can be tailored to the identified source of bleeding.

Despite controversy over pre-endoscopic antisecretory therapy, there is solid agreement regarding the importance of PPI administration following endoscopy in patients with confirmed peptic ulcer related bleeding.30 A meta-analysis of intravenous PPI therapy (80 mg bolus followed by 8 mg/hr) versus placebo for 72 hours after endoscopic hemostasis demonstrated a significant reduction in rebleeding (number needed to treat [NNT]=12), surgery (NNT=28), and mortality (NNT=45) in patients who had high-risk endoscopic stigmata (active bleeding, visible vessel, or adherent clot) at the time of their exam.34 Other endoscopic stigmata, such as a clean based or flat pigmented spot, have suitably low risk for rebleeding in themselves, and standard oral antisecretory therapy is sufficient for healing.35

3. Eradication of H. pylori infection

H. pylori infection is a well-established cofactor in the development of gastroduodenal ulcer disease and a primary independent risk factor for ulcer bleeding in epidemiological studies.36,37 Several high-quality publications, including the Maastricht consensus report and a recent Cochrane systematic review, suggest that the inclusion of a PPI along with two (triple therapy) or three (quadruple therapy) antibiotics provides a synergistic effect in the eradication of H. pylori and that PPIs are more effective in this role than H2RAs.38,39 This benefit has been ascribed to both increased bioavailability of acid-labile antibiotics40 and perhaps the direct inhibition of H. pylori growth.7

Long-term PPI therapy without eradication of H. pylori in infected patients may have potential attendant risks, although this remains controversial. It has been observed that acid-suppression alone alters the pattern of H. pylori associated gastritis to favor the gastric corpus and may facilitate the long-term development of atrophic gastritis.4143 Furthermore, there are animal data to suggest that PPI therapy without eradication may accelerate the potential for H. pylori to induce gastric carcinoma, though there is no substantive human correlation to this model.44,45 These data highlight the potential importance of eradication confirmation in infected patients who will continue antisecretory therapy beyond the short-course of antibiotics for other clinical purposes.

4. Prevention of NSAID induced gastroduodenal ulcers

Gastrointestinal (GI) toxicity from NSAIDs, including aspirin, is estimated to account for at least 2,600 deaths in the United States each year.46 In addition, the use or misuse of these drugs cause significant morbidity in the form of UGI symptoms, GI bleeding, and increased health care utilization.47 A 2008 multi-society guideline48 and an American College of Gastroenterology guideline issued in 200949 identified patients perceived to be at risk for NSAID induced GI toxicity who should be considered for prophylaxis. Present options for reducing the risk of NSAID associated GI toxicity in patients with obligate use of these agents include: the addition of misoprostol or acid antisecretory therapy, the use of a COX-2 selective NSAID, or any combination of these strategies.

While individual short term studies of H2RAs for prevention of NSAID induced ulcers have been published50,51 these results have not been consistent or observable over long-term patient follow-up. A meta-analysis of 112 individual RCTs by Koch et al.52 suggested that H2RAs demonstrated no evidence supporting the use of conventional dose H2RAs in a prophylactic role although high dose H2RAs may be beneficial.53 Once daily PPIs, on the other hand, were protective against the development of gastroduodenal ulcers (OR=0.35) in asymptomatic patients taking low-dose aspirin who underwent endoscopy.54

The best data in favor of PPI use come from two multicenter trials of higher-risk patients (n=1,429) taking daily NSAIDs. In these studies, the cumulative percentage of patients who developed ulcers at 6 months was substantially smaller in the group receiving esomeprazole (20 mg daily) (5.2%) versus placebo (17%). In addition, the use of a selective or nonselective COX inhibitor did not seem to impact whether patients were likely to develop an ulcer in the placebo group (17.1% vs 16.5%) while PPI co-therapy significantly reduced ulcer formation in both nonselective and selective NSAID users (6.8% vs 0.9%).55

5. Zollinger-Ellison syndrome

While the ultimate goal for patients in ZES is surgical excision of the neuroendocrine tumor, virtually every individual with this disease requires medical intervention to prevent acid-peptic complications due to the constitutive release of gastrin.56 The gastric acid hypersecretion associated with ZES can be controlled effectively using PPIs, though studies involving large numbers of patients are lacking due to the rare nature of this disease.

In a prospective 4-year study of 40 patients with ZES, patients underwent measured acid-output and had clinical endpoints assessed in response to titratable doses of omeprazole.57 Most patients in the study were able to have their acid output controlled with a once daily PPI dose, though nine required 60 mg twice daily for acid reduction. In a separate 13-year series involving 67 patients, greater than 90% of those enrolled were able to demonstrate long-term symptom control with a titration of lansoprazole (7.5 to 450 mg/day).58 Although the usual starting doses for PPIs in ZES are high (typically 60 to 120 mg daily), some patients can be down-titrated as low as 20 mg omeprazole once initial ulcer healing and symptom resolution has occurred.59

6. Erosive esophagitis

A systematic review of 15 epidemiological studies estimates the prevalence of gastroesophageal reflux disease to be somewhere between 10 and 20 percent in the Western world and around 5 percent in Asia.60,61 A subset of symptomatic patients will have endoscopic evidence of erosion, though classification of this finding varies among endoscopists.62 PPIs at typical dosages are exceedingly effective at inducing symptom remission and healing erosive esophagitis the overwhelming majority of patients.63,64

A Cochrane review of 134 trials which included 36,978 patients with erosive esophagitis demonstrated that the acute use of PPIs uniformly provided more rapid healing of esophagitis and symptom resolution compared with H2RAs and/or prokinetics. This was true regardless of the initial severity of esophagitis and was also independent of dose and treatment duration. In addition, there were no major observable differences in the overall effectiveness or side-effect profile among presently available PPIs for this indication.64

PPIs are also highly effective for the maintenance of healing in erosive esophagitis. Perhaps the most widely cited example of this finding was published in a landmark 1995 NEJM paper by Vigneri et al.65 In this prospective trial, 175 patients with endoscopically confirmed erosive esophagitis were randomized into one of five treatment arms after initial induction of healing by oral omeprazole (40 mg daily). These arms included: cisapride (10 mg three times per day), ranitidine (150 mg three times per day), omeprazole (20 mg daily), or either antisecretory agent in combination with cisapride. After 12 months of maintenance, omeprazole alone (or in combination with cisapride) was highly significantly superior in maintaining endoscopic remission to ranitidine alone (p<0.001), cisapride alone (p=0.003), or both ranitidine and cisapride (p=0.03).

Although this study suggested that effective doses for maintenance are generally similar to those required to induce initial healing,65 this has been subsequently challenged. With few exceptions, such as severe grades of esophagitis, half the healing dose of a PPI is often adequate for maintenance.66 Therefore we suggest that the lowest dose of PPI necessary to control symptoms should be the goal of long-term treatment. A transition to on demand therapy may even be appropriate for those who have milder grades of esophageal mucosal injury, as indicated by recent guidelines.67

7. Nonerosive reflux disease

NERD or endoscopy-negative reflux disease (ENRD) can be a particular challenge for the gastroenterologist. For a myriad of potential reasons, response rates to PPI and antisecretory treatment in general have been inferior in patients who have no endoscopically evident erosive disease. Despite this, PPI treatment for ENRD continues to offer an advantage over placebo (RR=0.71, 0.65–0.78) and H2RAs (RR=0.78, 0.62–0.97) with respect to heartburn control.68 Given the observation that PPIs can be effective even in the absence of endoscopic evidence of injury, many professional societies including the American College of Physicians,69 the American College of Gastroenterology,70 and the American Society for Gastrointestinal Endoscopy71 continue to support a trial of empiric therapy for undifferentiated gastro-esophageal reflux disease (GERD) unless alarming clinical indications for immediate upper endoscopy exist. When the absence of significant erosive disease is known, on-demand use of PPIs may be a reasonable option for control in patients who have intermittent but longer term ENRD symptoms.72,73

8. Functional dyspepsia

Functional dyspepsia, classified as either epigastric pain syndrome or postprandial distress syndrome accounts for approximately 5% of U.S. primary care visits per year.74 There is considerable ongoing debate as to the ideal initial diagnostic and/or management of uninvestigated dyspepsia. Despite this, treatment with omeprazole (20 mg daily) does have the potential to provide complete symptom relief in patients with dyspeptic symptoms and negative endoscopy when compared with placebo (38% vs 28%, p=0.002).75 Low PPI dosages seem to be adequate for this indication, as 15 mg of lansoprazole was observed to provide a similar benefit to 30 mg over a period of 4 and 8 weeks.76 A Cochrane review further supports the efficacy of PPI treatment in dyspepsia, and demonstrated a relative risk reduction in symptoms of 14% (95% confidence interval, 5% to 23%) when compared to placebo. Identifying individual patients who are likely to respond to antisecretory therapy in this setting is difficult, as there is frequently considerable symptom-based overlap between GERD, UGI dysmotility, and gastroduodenal acid-peptic disorders.77

CLINICAL LIMITATIONS OF PPIs

The consistent therapeutic superiority of PPIs over H2RAs, combined with pervasive distribution of these drugs in both over-the-counter and prescription forms, lends itself to the conclusion that these drugs cannot be improved. On the contrary, up to 50% of patients taking PPIs for nonerosive GERD are dissatisfied with their treatment due to unresolved symptoms.78 Although a multitude of non-PPI related factors may contribute to this inadequate response (UGI motility disorders, duodeno-gastric-esophageal reflux, visceral hypersensitivity, and patient hyper-vigilance), both the short plasma half-life and necessity for preprandial dosing are significant problems.

Among patients taking PPIs twice per day, nearly 40% increased their dosage because of persistent nocturnal symptoms.79 Overnight recovery of gastric acid secretion, termed “nocturnal acid breakthrough,” is frequently encountered with once-daily AM dosing of single release PPIs.80 The escalation of dosing to twice daily is often performed in keeping with both the American Gastroenterology Association67 and American College of Gastroenterology81 practice guidelines. Despite the frequency of this intervention, many patients continue to suffer breakthrough symptoms on a twice-daily regimen.82 Pharmacologically, esomeprazole 40 mg, given twice per day in healthy volunteers, still results in intragastric pH below 4 15% of the day.83

The importance of timing of drug dosing is also critically under-appreciated. As discussed previously, PPIs require expression of the proton pump along the parietal cell canaliculi membrane to establish binding. Cytosolic pumps, or those within lipid rafts, will not be accessible and therefore will not be affected. Approximately half of patients do not take their PPIs within 1 hour of breakfast79,82 and they may not have been instructed to do so by their physician or pharmacist.84 Poor compliance, combined with a narrow window to provide efficacy due to plasma half-life, may be an important cause of PPI failure.78

1. Long-term use of PPIs

Chronic use of high-dose PPIs is thought to affect the absorption of calcium, magnesium, and vitamin B12 since acid facilitates assimilation and ionization of less soluble forms of dietary calcium and release of food bound vitamin B12.85 In 2006, a nested, case-controlled series which included more than 13,000 patients from the United Kingdom suggested that the risk of hip fracture was increased with PPI use that exceeded 1 year (OR, 1.44) and was especially increased in those patients who had received high-dose PPIs (OR, 2.65).86 Although important, this study has received considerable criticism as there was heterogeneity among patients in study arms and a different prevalence of PPI use (e.g., PUD among fracture patients) which could explain the difference in observed fractures without ascribing causality. A later study which did not include patients who had major risk factors for hip fracture showed no association with PPI use and postulated that the earlier findings may have been due to confounding.87 This pattern of retrospective review and analysis has been consistent within the literature and ultimately the risk posed by PPI use seems unsettled.88 However, in 2010 the U.S. FDA required all manufacturers of PPIs to revise their product labels to include a warning about possible risk for fractures of the hip, wrist, and spine when used at high dose (more than once daily) or for a long duration (greater than 1 year).

Retrospective observational studies and their meta-analyses have also demonstrated a potential link between the use of PPIs and the development of community acquired pneumonia.89,90 A meta-analysis which included eight observational studies suggested that PPI use was associated with an 27% increased risk for either hospital or community acquired pneumonia (OR, 1.27) but that the greatest risk was within 7 days of beginning PPI treatment (OR, 3.95).89 This early risk had been demonstrated elsewhere91 and is interesting in that the outcome occurs before PPIs attain their full effectiveness. A more recent systematic review of trials including only patients prescribed PPI therapy for new-onset NSAID use revealed no increased risk for pneumonia. In this study, the authors argue that the previously observed association may have been in part due to protopathic bias either from inclusion of GERD patients (a risk factor for pneumonia) or from the misdiagnosis of early symptoms of pneumonia masquerading as GERD.90 In the absence of prospective, high-quality data, this association remains conjectural and does not influence our prescribing of antisecretory therapy to patients with a solid indication.

Further, there is evidence that PPI use may enhance patient susceptibility to a multitude of enteric infections including small intestinal bacterial overgrowth,92 Salmonella, Campylobacter jejuni, and Clostridium difficile.93 Infection with C. difficile (CDI) is of particular importance given the associated morbidity and escalating health burden posed by this problem. In 2012, a meta-analysis of 42 observational studies which included over 313,000 patients found that PPI use was associated with both incident (OR, 1.7) and recurrent (OR, 2.5) CDI.94 This observation led the U.S. FDA to issue a drug safety communication regarding the importance of PPI exposure, though the impact of both dose and duration of PPI treatment on this association remains unclear.

All PPIs are, to some extent, metabolized by the cytochrome P450 isozyme 2C19 as discussed previously. While this pharmacological property of PPIs has been well known for some time,14 it has more recently become a subject of considerable concern.15 Specifically, the potential for PPI induced enzyme inhibition to prevent the activation of clopidogrel (Plavix®) has led to a flurry of warnings, revisions, and publications. This interaction was first observed during in vitro studies which demonstrated that that synchronous administration of omeprazole diminished the effect of clopidogrel on platelet inhibition. In 2009, the FDA recommended avoiding the 1 last update 10 Jul 2020 the use of both drugs simultaneously.56 Despite this initial concern, there have been no in vivo data which has conclusively connected the use of omeprazole and clopidogrel with adverse clinical outcomes. In addition, this in vivo association has not been reliably demonstrated with other PPIs that are less dependent on 2C19 for their metabolism.95 Never the less given our knowledge of the pharmacodynamics, it is our practice to avoid omeprazole (and its stereoisomer, esomeprazole) in patients taking clopidogrel, in favor of alternatives such as lansoprazole, dexlansoprazole, or pantoprazole.All PPIs are, to some extent, metabolized by the cytochrome P450 isozyme 2C19 as discussed previously. While this pharmacological property of PPIs has been well known for some time,14 it has more recently become a subject of considerable concern.15 Specifically, the potential for PPI induced enzyme inhibition to prevent the activation of clopidogrel (Plavix®) has led to a flurry of warnings, revisions, and publications. This interaction was first observed during in vitro studies which demonstrated that that synchronous administration of omeprazole diminished the effect of clopidogrel on platelet inhibition. In 2009, the FDA recommended avoiding the use of both drugs simultaneously.56 Despite this initial concern, there have been no in vivo data which has conclusively connected the use of omeprazole and clopidogrel with adverse clinical outcomes. In addition, this in vivo association has not been reliably demonstrated with other PPIs that are less dependent on 2C19 for their metabolism.95 Never the less given our knowledge of the pharmacodynamics, it is our practice to avoid omeprazole (and its stereoisomer, esomeprazole) in patients taking clopidogrel, in favor of alternatives such as lansoprazole, dexlansoprazole, or pantoprazole.

In 2011 the FDA issued a class warning based on 61 individual case reports indicating that prolonged PPI use could result in low magnesium levels. While the mechanism responsible for and true incidence of PPI associated hypomagnesemia are unknown, FDA recommends checking magnesium levels periodically in patients expected to be on prolonged PPI treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics).96 Other recent FDA mandated PPI class warnings include PPI associated acute interstitial nephritis and the possibility of vitamin B12 deficiency with chronic (more than 3 years) daily PPI use.

2. Advances in PPI technology

A number of efforts have been made to overcome the inherent pharmacologic limitations of currently available PPIs, in particular their short plasma half-life (and therefore short duration of effect) and the need for preprandial dosing.

Tenatoprazole, the first imidazopyridine PPI, has demonstrated not only superior inhibitory activity on H+/K+ ATPase, but a substantially longer half-life (8 hours after a single dose and 14 after multiple doses) than currently available PPIs. This increase in half-life correspondingly increases the area under the plasma concentration curve (AUC) by over 20-fold, representing increased tissue exposure and thus duration of effect at the parietal cell cannaliculus.9799 While definitive trials of clinical efficacy are still unavailable, this revision to the structure of PPIs has intriguing future potential. Alterations in the formulation of available PPIs have also been utilized as a means of overcoming the challenges posed by short serum half-life. Rabeprazole-ER is a 50 mg capsule which contains 5-distinct 10 mg tablets designed to be degraded and absorbed at intervals throughout the small intestine and colon. In a study of healthy subjects, rabeprazole-ER showed superior control of nocturnal gastric acid secretion when compared to both esomeprazole and conventional delayed-release rabeprazole.11 However in two parallel double-blind studies, rabeprazole-ER was not superior esomeprazole for healing of severe erosive esophagitis (Los Angeles Classification grade C or D) and relief of associated heartburn100 so further clinical development of this compound was discontinued.

Dual-release dexlansoprazole is formulated to release drug in two separate pH controlled phases. Twenty-five percent of the drug dose is liberated in the proximal small intestine at a pH of 5.5, with pharmacokinetics (peak plasma concentration of 1 to 2 hours) similar to traditional enteric coated PPIs. This is followed by a second release of 75% of the drug dose in the more distal small intestine at a pH of 6.75 which provides a second serum peak at 5 to 6 hours after administration. Like tenatoprazole, this provides an overall increase in the AUC and thereby an overall higher mean 24-hour intragastric pH than its stereo-isomer lansoprazole.12 This offers a potential advantage to patients with obligate twice-daily dosing for symptom control,63 persistent nocturnal symptoms,101 or poor compliance with meal timing.

An alternate strategy to avoid the need for premeal dosing would be the inclusion of a stimulator of gastric acid secretion along with the PPI. Succinic acid exhibits pentagastrin like activity the 1 last update 10 Jul 2020 and has been FDA approved as a pharmaceutical excipient. In the past, this substance has been used in the food and beverage industry as an acidity regulator and is “generally recognized as safe.” In a preclinical trial of 36 healthy subjects, succinic acid combined with omeprazole (Vecam®) demonstrated significantly better nocturnal intragastric pH control than omeprazole alone.102 A Phase IIb clinical trial ({"":"","":{"":"","":""}}NCT01059383) evaluating patients with heartburn is currently ongoing.An alternate strategy to avoid the need for premeal dosing would be the inclusion of a stimulator of gastric acid secretion along with the PPI. Succinic acid exhibits pentagastrin like activity and has been FDA approved as a pharmaceutical excipient. In the past, this substance has been used in the food and beverage industry as an acidity regulator and is “generally recognized as safe.” In a preclinical trial of 36 healthy subjects, succinic acid combined with omeprazole (Vecam®) demonstrated significantly better nocturnal intragastric pH control than omeprazole alone.102 A Phase IIb clinical trial ({"":"","":{"":"","":""}}NCT01059383) evaluating patients with heartburn is currently ongoing.

CONCLUSIONS

Heartburn Remedies Other Natural Remedies (β˜‘ Heartburn Relief Foods) | Heartburn Remedies 10 Drinks To Avoidhow to Heartburn Remedies for PPIs represent an essential part of the modern gastroenterologist’s armament for combating everyday clinical problems. In general, they are highly efficacious in the treatment of acid-related disorders (Table 3). Despite this, the ubiquitous presence and indiscriminant use of PPIs has led to increased oversight among insurers and appropriate concern about the risk of indefinite hypochlorhydria and drug interaction. Careful consideration by the prescriber of appropriate indication, patient cofactors, and the expected dose and duration of treatment is a necessary part of responsible use of any drug, including PPIs.

Heartburn Remedies When To See A Doctor (⭐️ 6 Natural Remedies) | Heartburn Remedies Without Medicationhow to Heartburn Remedies for Table 3

Food and Drug Administration Approved Indications for Proton Pump Inhibitors

IndicationOmeprazoleEsomeprazoleLansoprazoleDexlansoprazolePantoprazoleRabeprazole
Gastro esophageal reflux disease
 Erosive esophagitis–healing
 Erosive esophagitis–maintenance
 Nonerosive reflux disease
Peptic ulcer disease
 Duodenal ulcer–healing
 Duodenal ulcer–maintenance
 Gastric ulcer–healing
 NSAID induced ulcers–healing
 NSAID induced ulcers–prophylaxis
 Zollinger-Ellison syndrome
Treatment of Helicobacter pylori
 Dual therapy
 Triple therapy
Pediatric population
 Any age (weight based dosing)
 Age greater than 5 years old
Special & off label uses
 Nonvariceal acute GI bleeding (IV)
 Administration via NG tubeX

NASID, nonsteroidal anti-inflammatory drugs; GI, gastrointestinal; IV, intravenous; NG, nasogastric.

Although very effective, PPIs are imperfect drugs owing, at least in part, to their pharmacologic limitations. Several novel approaches to overcome these limitations are being explored including the development of a non-benzimidole PPI and sophisticated delivery systems to mitigate the problems associated with their short half-life and obligatory preprandial dosing. Whether these approaches offer a clear clinical advantage or carry with them unanticipated problems, remains to be determined.

Footnotes

CONFLICTS for 1 last update 10 Jul 2020 OF INTERESTCONFLICTS OF INTEREST

Dr. Peura currently acts as a consultant and member of the speaker bureau for Takeda Pharmaceuticals and Pfizer Pharmaceuticals. Dr. Strand and Dr. Kim have no financial conflicts of interest.

REFERENCES

1. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial: Raberprazole Study Group. Am J Gastroenterol. 2000;95:1894–1899. doi: 10.1111/j.1572-0241.2000.02233.x. [PubMed] [CrossRef] Heartburn Remedies Doesn't Help (πŸ”₯ Foods To Avoid) | Heartburn Remedies Diseasehow to Heartburn Remedies for [Google Scholar]
2. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Heartburn Remedies Soothe The Pain (⭐️ 12 Tips) | Heartburn Remedies 9 Natural Remedieshow to Heartburn Remedies for Yale J Biol Med. 1996;69:159–174. [PMC free article] [PubMed] [Google Scholar]
3. U.S. Food and Drug Administration. Proton pump inhibitors: US Food and Drug Administration-approved indications and dosages for use in adults [Internet] Silver Spring: U.S. Food and Drug Administration; 2014. [cited 2016 Aug 31]. Available from: http://www.fda.gov/drugs. [Google Scholar][Google Scholar]
4. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Heartburn Remedies Warnings (πŸ‘ Natural Remedies For) | Heartburn Remedies Diethow to Heartburn Remedies for Gastroenterology. 1997;112:1798–1810. doi: 10.1053/gast.1997.v112.pm9178669. [PubMed] [CrossRef] [Google Scholar]
5. Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull. 2007;54:18–30. [PubMed] [Google the 1 last update 10 Jul 2020 Scholar]Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull. 2007;54:18–30. [PubMed] [Google Scholar]
6. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935–951. doi: 10.1007/s00228-008-0538-y. [PubMed] [CrossRef] [Google Scholar]
7. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000;38:243–270. doi: 10.2165/00003088-200038030-00004. [PubMed] [CrossRef] [Google Scholar]
8. Esplugues JV, Martí-Cabrera M, Ponce J. Safety of proton pump inhibitors. Med Clin (Barc) 2006;127:790–795. doi: 10.1157/13095825. [PubMed] [CrossRef] [Google Scholar]
9. Maffei M, Desmeules J, Cereda JM, Hadengue A. Side effects of proton pump inhibitors (PPIs) Rev Med Suisse. 2007;3:1934–1936. 1938. [PubMed] [Google Scholar]
10. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(Suppl 2):2–8. doi: 10.1111/j.1365-2036.2006.02943.x. [PubMed] [CrossRef] [Google Scholar]
11. Morelli G, Chen H, Rossiter G, Rege B, Lu Y. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment for 1 last update 10 Jul 2020 Pharmacol Ther. Aliment Pharmacol Ther. 2011;33:845–854. doi: 10.1111/j.1365-2036.2011.04580.x. [PubMed] [CrossRef] [Google Scholar]
12. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25:627–638. doi: 10.1185/03007990802693883. [PubMed] [CrossRef] [Google Scholar]
13. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):3–10. doi: 10.1046/j.1365-2036.1999.00019.x. [PubMed] [CrossRef] [Google Scholar]
14. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern the 1 last update 10 Jul 2020 Med. Ann Intern Med. 1998;129:1027–1030. doi: 10.7326/0003-4819-129-12-199812150-00006.Ann Intern the 1 last update 10 Jul 2020 Med. Ann Intern Med. 1998;129:1027–1030. doi: 10.7326/0003-4819-129-12-199812150-00006. [PubMed] [CrossRef] [Google Scholar]
15. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12:873–888. doi: 10.2217/pgs.11.4. [PubMed] [CrossRef] [Google for 1 last update 10 Jul 2020 Scholar][Google Scholar]
16. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(2 Suppl 1):S9–S31. doi: 10.1016/S0016-5085(00)70004-7. [PubMed] [CrossRef] [Google Scholar]
17. Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. Heartburn Remedies Remedies (πŸ”΄ 10 Easy) | Heartburn Remedies Naturallyhow to Heartburn Remedies for Am J Gastroenterol. 1997;92(4 the 1 last update 10 Jul 2020 Suppl):17S–19S.Am J Gastroenterol. 1997;92(4 Suppl):17S–19S. [PubMed] [Google the 1 last update 10 Jul 2020 Scholar][Google Scholar]
18. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis the 1 last update 10 Jul 2020 Sci. 1990;35:976–983. doi: 10.1007/BF01537246. [PubMed] [CrossRef] [Google Scholar]Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35:976–983. doi: 10.1007/BF01537246. [PubMed] [CrossRef] [Google Scholar]
19. Prichard PJ, Jones DB, Yeomans ND, Mihaly GW, Smallwood RA, Louis WJ. The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy. Br J Clin Pharmacol. 1986; for 1 last update 10 Jul 2020 2222:663–668. doi: 10.1111/j.1365-2125.1986.tb02955.x. [PMC free article] [PubMed] [CrossRef] Heartburn Remedies Warnings (πŸ”₯ Foods To Avoid) | Heartburn Remedies Foods To Avoidhow to Heartburn Remedies for [Google Scholar]
20. Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis the 1 last update 10 Jul 2020 Sci. Dig Dis Sci. 1995;40(2 Suppl):24S–49S. doi: 10.1007/BF02214870. [PubMed] [CrossRef] [Google Scholar]
21. Heartburn Remedies Soothe The Pain (πŸ‘ Diet For) | Heartburn Remedies List Ofhow to Heartburn Remedies for Eriksson S, Långström G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol. 1995;7:467–475. [PubMed] [Google Scholar]
22. Morgan DG, Burget DW, Howden CW, et al. Rates of duodenal ulcer (DU) healing by drug for 1 last update 10 Jul 2020 classes: a meta-analysis. Gastroenterology. 1993;104:A150. [Google Scholar]Morgan DG, Burget DW, Howden CW, et al. Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis. Gastroenterology. 1993;104:A150. [Google Scholar]
23. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol the 1 last update 10 Jul 2020 Hepatol. 1995;7:661–665.Eur J Gastroenterol Hepatol. 1995;7:661–665. [PubMed] [Google Scholar]
24. Prakash A, Faulds D. Rabeprazole. Heartburn Remedies The Discomfort (πŸ‘ GERD) | Heartburn Remedies Reflux Diseasehow to Heartburn Remedies for Drugs. 1998;55:261–267. doi: 10.2165/00003495-199855020-00009. [PubMed] [CrossRef] [Google for 1 last update 10 Jul 2020 Scholar][Google Scholar]
25. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Heartburn Remedies Foods To Avoid (β˜‘ Foods That Fight Hearbturn) | Heartburn Remedies Solutionshow to Heartburn Remedies for Drugs. 1996; for 1 last update 10 Jul 2020 5151:460–482. doi: 10.2165/00003495-199651030-00012. [PubMed] [CrossRef] Heartburn Remedies Remedy Relief (πŸ”₯ 9 Ways To Relieve) | Heartburn Remedies Acid Refluxhow to Heartburn Remedies for [Google Scholar]
26. Lauritsen K, Andersen BN, Laursen LS, et al. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse: double-blind comparative trial. Heartburn Remedies Other Natural Remedies (⭐️ What Is The Best) | Heartburn Remedies What Is The Besthow to Heartburn Remedies for Gastroenterology. 1991;100:663–669. [PubMed] Heartburn Remedies How To (πŸ‘ Heartburn Remedies) | Heartburn Remedies Home Remedyhow to Heartburn Remedies for [Google Scholar]
27. Lanza F, Goff J, Silvers D, et al. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. Dig for 1 last update 10 Jul 2020 Dis Sci. Dig Dis Sci. 1997;42:2529–2536. doi: 10.1023/A:1018868713520. [PubMed] [CrossRef] [Google Scholar]
28. Dammann HG, Walter TA. Efficacy of continuous therapy for peptic ulcer in controlled clinical trials. Heartburn Remedies Solutions (πŸ”₯ Side Effects) | Heartburn Remedies Home Remedies Forhow to Heartburn Remedies for Aliment Pharmacol Ther. 1993;7(Suppl 2):17–25. doi: 10.1111/j.1365-2036.1993.tb00595.x. [PubMed] [CrossRef] [Google Scholar]
29. Heartburn Remedies Naturally (⭐️ Causes) | Heartburn Remedies To Eathow to Heartburn Remedies for Katschinski B, Logan R, Davies J, Faulkner G, Pearson J, Lang-man M. Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci. 1994;39:706–712. doi: 10.1007/BF02087411. [PubMed] [CrossRef] [Google Scholar]
30. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345–60. doi: 10.1038/ajg.2011.480. [PubMed] [CrossRef] [Google Scholar]
31. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–113. doi: 10.7326/0003-4819-152-2-201001190-00009. [PubMed] [CrossRef] [Google Scholar]
32. Heartburn Remedies Unexpected Foods (πŸ”΄ When To See A Doctor) | Heartburn Remedies Remedy Reliefhow to Heartburn Remedies for Barkun A, Bardou M, Marshall JK Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper for 1 last update 10 Jul 2020 gastrointestinal bleeding. Ann Intern Med. 2003;139:843–857. doi: 10.7326/0003-4819-139-10-200311180-00012.Ann Intern Med. 2003;139:843–857. doi: 10.7326/0003-4819-139-10-200311180-00012. [PubMed] [CrossRef] [Google Scholar]Barkun A, Bardou M, Marshall JK Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2003;139:843–857. doi: 10.7326/0003-4819-139-10-200311180-00012.Ann Intern Med. 2003;139:843–857. doi: 10.7326/0003-4819-139-10-200311180-00012. [PubMed] [CrossRef] [Google Scholar]
33. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(7):CD005415. [PMC free article] [PubMed] [Google Scholar]
34. Heartburn Remedies Home Remedies (πŸ”΄ 10 Foods To Eat) | Heartburn Remedies Heartburn Home Remedieshow to Heartburn Remedies for Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009;7:33–47. doi: 10.1016/j.cgh.2008.08.016. [PubMed] [CrossRef] [Google Scholar]
35. Heartburn Remedies Home Remedies For (β˜‘ Heartburn During Pregnancy) | Heartburn Remedies Solutionshow to Heartburn Remedies for Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994;331:717–727. doi: 10.1056/NEJM199409153311107. [PubMed] [CrossRef] [Google Scholar]
36. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89(8 Suppl):S116–S128. [PubMed] [Google Scholar]
37. Shimada T, Yamagata M, Hiraishi H. Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Nihon Rinsho. 2007;65:1824–1829. [PubMed] Heartburn Remedies Acid Reflux (πŸ”₯ Treatments) | Heartburn Remedies Diseasehow to Heartburn Remedies for [Google Scholar]
38. Heartburn Remedies 23+ Home Remedies (β˜‘ Home Remedies For) | Heartburn Remedies Acid Refluxhow to Heartburn Remedies for Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus report. Gut. 2012;61:646–664. doi: 10.1136/gutjnl-2012-302084. [PubMed] [CrossRef] [Google Scholar]
39. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;(12):CD008337. [PubMed] [Google Scholar]
40. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm the 1 last update 10 Jul 2020 Assoc (Wash) J Am Pharm Assoc (Wash) 2000;40:52–62. doi: 10.1016/S1086-5802(16)31036-1. [PubMed] [CrossRef] [Google the 1 last update 10 Jul 2020 Scholar][Google Scholar]
41. Lundell L, Havu N, Miettinen P, et for 1 last update 10 Jul 2020 al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006;23:639–647. doi: 10.1111/j.1365-2036.2006.02792.x. [PubMed] [CrossRef] [Google Scholar]Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006;23:639–647. doi: 10.1111/j.1365-2036.2006.02792.x. [PubMed] [CrossRef] [Google Scholar]
42. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5:206–214. doi: 10.1046/j.1523-5378.2000.00032.x. [PubMed] [CrossRef] [Google Scholar]
43. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018–1022. doi: 10.1056/NEJM199604183341603. [PubMed] [CrossRef] [Google Scholar]Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018–1022. doi: 10.1056/NEJM199604183341603. [PubMed] [CrossRef] [Google Scholar]
44. Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut. 2011;60:624–630. doi: 10.1136/gut.2010.207662. [PubMed] [CrossRef] [Google Scholar]
45. Heartburn Remedies 10 Easy (πŸ”₯ Acid Reflux Every Day) | Heartburn Remedies Help Relievehow to Heartburn Remedies for Fox JG, Kuipers EJ. Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil. Gut. 2011; the 1 last update 10 Jul 2020 6060:567–568. doi: 10.1136/gut.2010.229286. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
46. Heartburn Remedies 10 Drinks To Avoid (πŸ”₯ Naturally) | Heartburn Remedies Instant Heartburn Reliefhow to Heartburn Remedies for Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787–796. doi: 10.7326/0003-4819-115-10-787.Ann Intern Med. 1991;115:787–796. doi: 10.7326/0003-4819-115-10-787. [PubMed] [CrossRef] [Google Scholar]
47. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997;Heartburn Remedies Naturally (πŸ”΄ Naturally Treat) | Heartburn Remedies Quick Reliefhow to Heartburn Remedies for 112:1000–1016. doi: 10.1053/gast.1997.v112.pm9041264. [PubMed] [CrossRef] [Google Scholar]
48. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 Expert Consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents. Heartburn Remedies 9 Home Remedies (πŸ‘ 9 Ways To Relieve) | Heartburn Remedies Disease Treatmenthow to Heartburn Remedies for J Am Coll Cardiol. 2008;52:1502–1517. doi: 10.1016/j.jacc.2008.08.002. [PubMed] [CrossRef] [Google Scholar]
49. Lanza FL, Chan FK, Quigley EM Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–738. doi: 10.1038/ajg.2009.115. [PubMed] [CrossRef] Heartburn Remedies 7 Natural (πŸ”΄ Without Medication) | Heartburn Remedies Stops Acid Refluxhow to Heartburn Remedies for [Google Scholar]
50. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334:1435–1439. doi: 10.1056/NEJM199605303342204. [PubMed] [CrossRef] [Google Scholar]
51. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;Heartburn Remedies How To Naturally Treat (πŸ”₯ Foods To Eat And Avoid) | Heartburn Remedies Foods To Avoidhow to Heartburn Remedies for 374:119–125. doi: 10.1016/S0140-6736(09)61246-0. [PubMed] [CrossRef] [Google Scholar]
52. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: a meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996;156:2321–2332. doi: 10.1001/archinte.1996.00440190069008. [PubMed] [CrossRef] [Google Scholar]
53. Tuskey A, Peura D. The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S6. doi: 10.1186/ar4178. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Tamura A, Murakami K, Kadota J OITA-GF Study Investigators. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM. 2011;104:133–139. doi: 10.1093/qjmed/hcq169. [PubMed] [CrossRef] [Google Scholar]
55. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J for 1 last update 10 Jul 2020 Gastroenterol. 2006; the 1 last update 10 Jul 2020 101101:701–710. doi: 10.1111/j.1572-0241.2006.00499.x.Am J Gastroenterol. 2006; the 1 last update 10 Jul 2020 101101:701–710. doi: 10.1111/j.1572-0241.2006.00499.x. [PubMed] [CrossRef] Heartburn Remedies 6 Natural Remedies (β˜‘ GERD Diet) | Heartburn Remedies Heartburn During Pregnancyhow to Heartburn Remedies for [Google Scholar]
56. Jensen RT, Fraker DL. Zollinger-Ellison syndrome: advances in treatment of gastric hypersecretion and the gastrinoma. JAMA. 1994;271:1429–1435. doi: 10.1001/jama.1994.03510420061035. [PubMed] [CrossRef] Heartburn Remedies Tests (πŸ‘ Treatments For) | Heartburn Remedies To Avoidhow to Heartburn Remedies for [Google Scholar]
57. Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology. 1989;97:827–836. doi: 10.1016/0016-5085(89)91485-6. [PubMed] [CrossRef] [Google Scholar]
58. Heartburn Remedies Acid Reflux (πŸ”΄ Disease) | Heartburn Remedies Heartburn Home Remedieshow to Heartburn Remedies for Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3:39–48. doi: 10.1016/S1542-3565(04)00606-8. [PubMed] [CrossRef] [Google Scholar]
59. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103:1498–1508. doi: 10.1016/0016-5085(92)91170-9. [PubMed] [CrossRef] [Google Scholar]
60. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880. doi: 10.1136/gutjnl-2012-304269.Gut. 2014;63:871–880. doi: 10.1136/gutjnl-2012-304269. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
61. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–717. doi: 10.1136/gut.2004.051821.Gut. 2005;54:710–717. doi: 10.1136/gut.2004.051821. [PMC free article] [PubMed] [CrossRef] [Google Scholar][Google Scholar]
62. Lee SH, Jang BI, Kim KO, et al. Endoscopic experience improves interobserver agreement in the grading of esophagitis by Los Angeles classification: conventional endoscopy and optimal band image system. Gut Liver. 2014;Heartburn Remedies Foods That Can Help (πŸ”΄ 9 Ways To Relieve) | Heartburn Remedies 7 Naturalhow to Heartburn Remedies for 8:154–159. doi: 10.5009/gnl.2014.8.2.154. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Fass R, Inadomi J, Han C, Mody R, O’Neil J, Perez MC. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10:247–253. doi: 10.1016/j.cgh.2011.11.021. [PubMed] [CrossRef] [Google Scholar]
64. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Heartburn Remedies Heartburn Symptoms (πŸ”΄ Heartburn) | Heartburn Remedies Disease Treatmenthow to Heartburn Remedies for Cochrane Database Syst Rev. 2007;(2):CD003244. [PubMed] [Google Scholar]
65. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–1110. doi: 10.1056/NEJM199510263331703. [PubMed] [CrossRef] [Google Scholar]
66. Kushner PR, Peura DA. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect? Adv Ther. 2011;28:367–388. doi: 10.1007/s12325-011-0013-5. [PubMed] [CrossRef] [Google Scholar]
67. Kahrilas PJ, Shaheen NJ, Vaezi MF American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological the 1 last update 10 Jul 2020 Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392–1413.e5. doi: 10.1053/j.gastro.2008.08.044. [PubMed] [CrossRef] [Google Scholar]Kahrilas PJ, Shaheen NJ, Vaezi MF American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392–1413.e5. doi: 10.1053/j.gastro.2008.08.044. [PubMed] [CrossRef] [Google Scholar]
68. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;(5):CD002095. [PMC free article] [PubMed] [Google Scholar]
69. Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012;157:808–816. doi: 10.7326/0003-4819-157-11-201212040-00008.Ann Intern Med. 2012;157:808–816. doi: 10.7326/0003-4819-157-11-201212040-00008. [PubMed] [CrossRef] [Google Scholar]
70. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013; the 1 last update 10 Jul 2020 108108:308–328. doi: 10.1038/ajg.2012.444. [PubMed] [CrossRef] Heartburn Remedies Heartburn (πŸ”₯ Best) | Heartburn Remedies Heartburnhow to Heartburn Remedies for [Google Scholar]
71. Standards of Practice Committee. Lichtenstein DR, Cash BD, et al. Role of endoscopy in the management of GERD. Gastrointest Endosc. 2007;Heartburn Remedies Symptoms (β˜‘ Disease) | Heartburn Remedies 11 Foods That Helphow to Heartburn Remedies for 66:219–224. doi: 10.1016/j.gie.2007.05.027. [PubMed] [CrossRef] [Google Scholar]
72. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007;102:642–653. doi: 10.1111/j.1572-0241.2006.00998.x.Am J Gastroenterol. 2007;102:642–653. doi: 10.1111/j.1572-0241.2006.00998.x. [PubMed] [CrossRef] [Google Scholar][Google Scholar]
73. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’ Aliment the 1 last update 10 Jul 2020 Pharmacol Ther. Aliment Pharmacol Ther. 2007;26:195–204. doi: 10.1111/j.1365-2036.2007.03381.x. [PubMed] [CrossRef] [Google Scholar]
74. Nyrén O, Lindberg G, Lindström E, Marké LA, Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics. 1992;1:312–324. doi: 10.2165/00019053-199201050-00003. [PubMed] [CrossRef] [Google Scholar]Nyrén O, Lindberg G, Lindström E, Marké LA, Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics. 1992;1:312–324. doi: 10.2165/00019053-199201050-00003. [PubMed] [CrossRef] [Google Scholar]
75. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies) Heartburn Remedies Heartburn Relief (πŸ‘ Foods That Fight Hearbturn) | Heartburn Remedies Doesn't Helphow to Heartburn Remedies for Aliment Pharmacol Ther. 1998;12:1055–1065. doi: 10.1046/j.1365-2036.1998.00410.x. [PubMed] [CrossRef] [Google Scholar]
76. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med. 2004; the 1 last update 10 Jul 2020 116116:740–748. doi: 10.1016/j.amjmed.2004.01.008. [PubMed] [CrossRef] [Google Scholar]
77. Heartburn Remedies Chronic Heartburn (β˜‘ Home Remedy Solutions) | Heartburn Remedies Foods That Fight Hearbturnhow to Heartburn Remedies for Stanghellini V, Frisoni C. Editorial: reflux, dyspepsia, and Rome III (or Rome IV?) Am J Gastroenterol. 2010;105:2632–2634. doi: 10.1038/ajg.2010.354. [PubMed] [CrossRef] [Google Scholar]
78. Heartburn Remedies Why (⭐️ Heartburn Relief Foods) | Heartburn Remedies Heartburn Remedieshow to Heartburn Remedies for Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther. 2005;22:79–94. doi: 10.1111/j.1365-2036.2005.02531.x. [PubMed] [CrossRef] [Google Scholar]Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther. 2005;22:79–94. doi: 10.1111/j.1365-2036.2005.02531.x. [PubMed] [CrossRef] [Google Scholar]
79. Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55:3415–3422. doi: 10.1007/s10620-010-1209-2. [PubMed] [CrossRef] [Google Scholar]
80. Tutuian R, Castell DO. Nocturnal acid breakthrough: approach to management. MedGenMed. 2004;Heartburn Remedies 7 Home Remedies (β˜‘ Nighttime) | Heartburn Remedies Naturally Treathow to Heartburn Remedies for the 1 last update 10 Jul 2020 66:11. Heartburn Remedies Remedies (⭐️ What Causes Heartburn) | Heartburn Remedies Home Remedies Forhow to Heartburn Remedies for [PMC free article] [PubMed] [Google Scholar]
81. DeVault KR, Castell DO American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastro-esophageal reflux disease. Am J Gastroenterol. 2005;100:190–200. doi: 10.1111/j.1572-0241.2005.41217.x. [PubMed] [CrossRef] [Google Scholar]
82. Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009;25:1869–1878. doi: 10.1185/03007990903035745. [PubMed] [CrossRef] [Google Scholar]
83. Heartburn Remedies Disease (β˜‘ 10 Drinks To Avoid) | Heartburn Remedies Symptomshow to Heartburn Remedies for Yuan Y, Hunt R. Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am J Gastroenterol. 2008;103(Suppl 1):S50. [Google Scholar]
84. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100:1237–1242. doi: 10.1111/j.1572-0241.2005.41364.x. [PubMed] [CrossRef] [Google Scholar]
85. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448–457. doi: 10.1007/s11894-010-0141-0. [PMC free the 1 last update 10 Jul 2020 article][PMC free article] [PubMed] [CrossRef] [Google Scholar]Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448–457. doi: 10.1007/s11894-010-0141-0. [PMC free the 1 last update 10 Jul 2020 article][PMC free article] [PubMed] [CrossRef] [Google Scholar]
86. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953. doi: 10.1001/jama.296.24.2947. [PubMed] [CrossRef] [Google Scholar]
87. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Heartburn Remedies Cure Your Acid Reflux (πŸ‘ Disease) | Heartburn Remedies Home Remedies Forhow to Heartburn Remedies for Pharmacotherapy. 2008;28:951–959. doi: 10.1592/phco.28.8.951. [PubMed] [CrossRef] [Google Scholar]
88. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–1218. doi: 10.1038/ajg.2011.113. [PubMed] [CrossRef] Heartburn Remedies Natural Remedies (πŸ‘ 9 Natural Remedies) | Heartburn Remedies Stops Acid Refluxhow to Heartburn Remedies for [Google Scholar]
89. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. the 1 last update 10 Jul 2020 CMAJ. CMAJ. 2011;183:310–319. doi: 10.1503/cmaj.092129. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
90. Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63:552–558. doi: 10.1136/gutjnl-2013-304738. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
91. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Heartburn Remedies Herbal Remedies (πŸ”΄ Treatment) | Heartburn Remedies 7 Natural GERDhow to Heartburn Remedies for Ann Intern Med. 2008;149:391–398. doi: 10.7326/0003-4819-149-6-200809160-00005. [PubMed] [CrossRef] [Google Scholar]
92. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483–490. doi: 10.1016/j.cgh.2012.12.011. [PubMed] [CrossRef] [Google Scholar]
93. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269–1281. doi: 10.1111/j.1365-2036.2011.04874.x. [PubMed] [CrossRef] [Google Scholar]
94. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;Heartburn Remedies 11 Foods That Cause (πŸ”΄ 6 Natural Remedies) | Heartburn Remedies GERDhow to Heartburn Remedies for 107:1011–1019. doi: 10.1038/ajg.2012.108. [PubMed] [CrossRef] [Google Scholar]
95. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105:2533–2549. doi: 10.1038/ajg.2010.445. [PubMed] [CrossRef] [Google Scholar]
96. U.S. Food and Drug Administration. FDA drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs) [Internet] Silver Spring: U.S. Food and Drug Administration; 2011. [cited 2012 Feb 23]. Available for 1 last update 10 Jul 2020 from: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. [Google Scholar]U.S. Food and Drug Administration. FDA drug safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs) [Internet] Silver Spring: U.S. Food and Drug Administration; 2011. [cited 2012 Feb 23]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. [Google Scholar]
97. Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther. 2005;Heartburn Remedies Side Effects (πŸ‘ 11 Foods That Help) | Heartburn Remedies How To Get Ridhow to Heartburn Remedies for 21:575–582. doi: 10.1111/j.1365-2036.2005.02381.x. [PubMed] [CrossRef] Heartburn Remedies Quick Relief (πŸ”₯ Side Effects) | Heartburn Remedies GERDhow to Heartburn Remedies for [Google Scholar]
98. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am for 1 last update 10 Jul 2020 J Gastroenterol. Am J Gastroenterol. 2005;100:1949–1956. doi: 10.1111/j.1572-0241.2005.41956.x. [PubMed] [CrossRef] Heartburn Remedies Foods To Avoid (πŸ”₯ 6 Natural Remedies) | Heartburn Remedies 10 Foodshow to Heartburn Remedies for [Google Scholar]
99. Thomson AB, Cohen P, Ficheux H, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol the 1 last update 10 Jul 2020 Ther. 2006;23:1179–1187. doi: 10.1111/j.1365-2036.2006.02781.x. [PubMed] [CrossRef] [Google Scholar]Thomson AB, Cohen P, Ficheux H, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23:1179–1187. doi: 10.1111/j.1365-2036.2006.02781.x. [PubMed] [CrossRef] [Google Scholar]
100. Laine L, Katz PO, Johnson DA, et al. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis. The results of two double-blind studies. Aliment Pharmacol Ther. 2011; the 1 last update 10 Jul 2020 3333:203–212. doi: 10.1111/j.1365-2036.2010.04516.x. [PubMed] [CrossRef] [Google Scholar][Google Scholar]
101. Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106:421–431. doi: 10.1038/ajg.2010.458. [PubMed] [CrossRef] [Google Scholar]
102. Chowers Y, Atarot T, Pratha VS, Fass R. The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH. Neurogastroenterol the 1 last update 10 Jul 2020 Motil. 2012;24:426–431.e209. doi: 10.1111/j.1365-2982.2012.01884.x.Neurogastroenterol Motil. 2012;24:426–431.e209. doi: 10.1111/j.1365-2982.2012.01884.x. [PubMed] [CrossRef] Heartburn Remedies Herbs (πŸ”₯ 10 Home Remedies) | Heartburn Remedies Heartburn Home Remedieshow to Heartburn Remedies for [Google Scholar][Google Scholar]

Articles from Gut the 1 last update 10 Jul 2020 and LiverGut and Liver are provided here courtesy of The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, the Korean Society of Pancreatobiliary Disease, and the Korean Society of Gastrointestinal Cancer